All News

Early-life obesity increases the risk of several different types of cancer developing later in life.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

In its multiple-ascending dose trial, ARO-HBV demonstrated reductions in circulating hepatitis B virus surface antigen.

Study identifies a potential association between azathioprine and the mutational signature found in cases of cutaneous squamous cell carcinoma.

The FDA is taking new steps to better ensure the quality of compounded drugs, while also preserving patient access to these medications.

Study shows a novel treatment approach that could prevent gene changes associated with the disease.

Top news of the day from across the health care landscape.

Officials with the FDA recently granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.

Top news of the day from across the health care landscape.

More than half of Americans tested misused their prescription drugs in 2017.

Treatment with tezepelumab reduced annual asthma exacerbation rates in patients with severe asthma without an eosinophilic phenotype.

Public action to prevent suicide becomes crucial, as suicide rates rise in almost every state.

Our inability to convince anti-vaccination individuals that immunization is prudent has resulted in increased incidences of some vaccine preventable diseases.

Treatment with ibudilast reduced the progression of brain atrophy in patients with progressive multiple sclerosis compared with a placebo.

Officials with the FDA have approved a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film (Cassipa, Teva Pharmaceuticals) for the maintenance treatment of opioid dependence

Officials with the FDA have approved a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film for the maintenance treatment of opioid dependence.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

At the International Pharmaceutical Federation (FIP) World Congress in Glasgow Scotland, speakers reviewed principles of pharmacogenomics and demonstrated useful strategies for utilizing pharmacogenomics in a clinical setting.

GADIS was first launched in December 2011 to connect practicing DI specialists to each other and promote information sharing among pharmacists.

Officials with the FDA have approved Grifols’ new formulation of immune globulin (GamaSTAN) for hepatitis A virus and measles post-exposure prophylaxis.

Officials with the FDA have approved a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film (Cassipa, Teva Pharmaceuticals) for the maintenance treatment of opioid dependence.

Presenters delved into the topic of biological drugs and gene therapy during the recent International Pharmaceutical Federation (FIP) World Congress in Glasgow Scotland.

Two speakers faced off during a session at the 78th FIP World Congress of Pharmacy and Pharmaceutical Sciences in Glasgow, Scotland, about whether these products have merit.

The new formulation is the only immune globulin available in the United States that is approved for post-exposure protection against hepatitis A and measles.

The role of pharmacists in these causes and natural disasters continues to evolve as organizers and policymakers understand the value that they bring to these events.

Although statins have been linked to benefits among older patients with cardiovascular disease, the results of a recent study indicate that there is insufficient evidence to recommend the drug class’ widespread use in healthy adults over the age of 75.

Ozanimod reduced the number of brain lesions and lowered relapse rates in patients with relapsing multiple sclerosis.